Clinical Trial Update: Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing aprepitant to hydroxyzine in persistent aquagenic pruritus for patients with myeloproliferative neoplasms has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aquagenic Pruritus
• Myeloproliferative Neoplasms

Drugs mentioned

• Aprepitant (aprepitant)
• Hydroxyzine (hydroxyzine)

Snippet

Sponsor: University Hospital, Brest | Conditions: Myeloproliferative Disorder, Aquagenic Pruritus | Phase 3 | Status: COMPLETED